Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

Affiliations

• ¹ Barts Cancer Institute, Queen Mary University of London, London, UK. thomas.powles1@nhs.net.
• ² Dana-Farber Cancer Center, Boston, MA, USA.
• ³ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ⁴ University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ⁵ City of Hope National Medical Center, Duarte, CA, USA.
• ⁶ Brigham and Women's Hospital, Boston, MA, USA.
• ⁷ Exelixis, Inc, Alameda, CA, USA.
• ⁸ Gustave-Roussy, Villejuif, France.
• ⁹ Duke Cancer Institute, Durham, NC, USA.